Top

12-04-2024 | Lupus Nephritis | Educational Review

Do we really need cyclophosphamide for lupus nephritis?

Authors: Scott E. Wenderfer, Jennifer C. Cooper

Abstract

A 14-year-old patient presents with hematuria and proteinuria. Clinical evaluation reveals a positive anti-nuclear antibody titer, positive anti-double stranded DNA antibody and hypocomplementemia. Systemic lupus erythematosus (SLE) is diagnosed based on the 2019 EULAR/ACR (European League Against Rheumatism/American College of Rheumatology) classification criteria (Aringer et al. Arthritis Rheumatol 71:1400–1412, 2019). A kidney biopsy is performed that confirms the presence of immune complex glomerulonephritis, ISN-RPS (International Society of Nephrology/Renal Pathology Society) class IV (Bajema et al. Kidney Int 93:789–796, 2018). According to the latest clinical practice guidelines (Rovin et al. Kidney Int 100:753–779, 2021; Fanouriakis et al. Ann Rheum Dis 83:15–29, 2023), there are alternatives to treating this patient with cyclophosphamide. But what if this patient also presented with oliguria and volume overload requiring intensive care and dialysis? What if this patient also presented with altered mental status and seizures, and was diagnosed with neuropsychiatric lupus? What if this patient was also diagnosed with a pulmonary hemorrhage and respiratory failure? The clinical practice guidelines do not address these scenarios that are not uncommon in patients with SLE. Moreover, in some countries worldwide, patients do not have the privilege of access to biologics or more expensive alternatives. The purpose of this review is to evaluate the contemporary options for initial treatment of nephritis in patients with SLE.

Wenderfer SE, Ruth NM, Brunner HI (2017) Advances in the care of children with lupus nephritis. Pediatr Res 81:406–414. https://doi.org/10.1038/pr.2016.247CrossRefPubMed

Hiraki LT, Feldman CH, Liu J et al (2012) Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US medicaid beneficiary population. Arthritis Rheumatol 64:2669–2676. https://doi.org/10.1002/art.34472CrossRef

Wenderfer SE, Chang JC, Goodwin Davies A et al (2022) Using a multi-institutional pediatric learning health system to identify systemic lupus erythematosus and lupus nephritis: development and validation of computable phenotypes. Clin J Am Soc Nephrol 17:65–74. https://doi.org/10.2215/CJN.07810621CrossRefPubMedPubMedCentral

Garnier C, Ribes D, Chauveau D et al (2018) Zoster after cyclophosphamide for systemic lupus erythematosus or vasculitis: incidence, risk factors, and effect of antiviral prophylaxis. J Rheumatol 45:1541–1548. https://doi.org/10.3899/jrheum.180310CrossRefPubMed

Chan EY, Yap DY, Wong WH et al (2023) Renal relapse in children and adolescents with childhood-onset lupus nephritis: a 20-year study. Rheumatology. https://doi.org/10.1093/rheumatology/kead447CrossRef

Quinlan C, Marks SD, Tullus K (2016) Why are kids with lupus at an increased risk of cardiovascular disease? Pediatr Nephrol 31:861–883. https://doi.org/10.1007/s00467-015-3202-7CrossRefPubMed

Chen YE, Korbet SM, Katz RS et al (2008) Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 3:46–53CrossRefPubMedPubMedCentral

De Mutiis C, Wenderfer SE, Orjuela A et al (2021) Defining renal remission in an international cohort of 248 children and adolescents with lupus nephritis. Rheumatology 61:2563–2571. https://doi.org/10.1093/rheumatology/keab746CrossRef

Askenazi D, Myones B, Kamdar A et al (2007) Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy. Pediatr Nephrol 22:981–986. https://doi.org/10.1007/s00467-007-0447-9CrossRefPubMed

10.

Hiraki LT, Lu B, Alexander SR et al (2011) End-stage renal disease due to lupus nephritis among children in the US, 1995–2006. Arthritis Rheumatol 63:1988–1997. https://doi.org/10.1002/art.30350CrossRef

11.

Hagelberg S, Lee Y, Bargman J et al (2002) Longterm followup of childhood lupus nephritis. J Rheumatol 29:2635–2642PubMed

12.

Freedman BI, Langefeld CD, Andringa KK et al (2014) End-stage kidney disease in African Americans with lupus nephritis associates with APOL1. Arthritis Rheumatol 66:390–396. https://doi.org/10.1002/art.38220CrossRefPubMedPubMedCentral

13.

Petrovic G, Pasic S, Soldatovic I (2023) Association of antiphospholipid antibodies with clinical manifestations in children with systemic lupus erythematosus. J Clin Med 12:1424. https://doi.org/10.3390/jcm12041424CrossRefPubMedPubMedCentral

14.

Zappitelli M, Duffy C, Bernard C et al (2004) Clinicopathological study of the WHO classification in childhood lupus nephritis. Pediatr Nephrol 19:503–510. https://doi.org/10.1007/s00467-004-1419-yCrossRefPubMed

15.

Marks SD, Sebire NJ, Pilkington C et al (2007) Clinicopathological correlations of paediatric lupus nephritis. Pediatr Nephrol 22:77–83. https://doi.org/10.1007/s00467-006-0296-yCrossRefPubMed

16.

Zappitelli M, Duffy CM, Bernard C et al (2008) Evaluation of activity, chronicity and tubulointerstitial indices for childhood lupus nephritis. Pediatr Nephrol 23:83–91. https://doi.org/10.1007/s00467-007-0619-7CrossRefPubMed

17.

Lee BS, Cho HY, Kim EJ et al (2007) Clinical outcomes of childhood lupus nephritis: a single center’s experience. Pediatr Nephrol 22:222–231. https://doi.org/10.1007/s00467-006-0286-0CrossRefPubMed

18.

Chabner B, Allegra C, Curt G et al (1996) Antineoplastic agents. In: Hardman J, Limbird L, Molinoff P, Ruddon R, Gilman A (eds) Goodman and Gilman’s the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 1233–1287

19.

Austin HA 3rd, Klippel JH, Balow JE et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619. https://doi.org/10.1056/NEJM198603063141004CrossRefPubMed

20.

Ginzler EM, Dooley MA, Aranow C et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228CrossRefPubMed

21.

Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112. https://doi.org/10.1681/ASN.2008101028CrossRefPubMedPubMedCentral

22.

Tunnicliffe DJ, Palmer SC, Henderson L et al (2018) Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev 6:CD002922. https://doi.org/10.1002/14651858.CD002922.pub4CrossRefPubMed

23.

Silva CA, Deen ME, Febronio MV et al (2011) Hormone profile in juvenile systemic lupus erythematosus with previous or current amenorrhea. Rheumatol Int 31:1037–1043. https://doi.org/10.1007/s00296-010-1389-2CrossRefPubMed

24.

Kallenberg CGM (2012) Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis? Ann Rheum Dis 72:ii62–ii65. https://doi.org/10.1136/annrheumdis-2012-202195CrossRefPubMed

25.

Gajjar R, Miller SD, Meyers KE et al (2015) Fertility preservation in patients receiving cyclophosphamide therapy for renal disease. Pediatr Nephrol 30:1099–1106. https://doi.org/10.1007/s00467-014-2897-1CrossRefPubMed

26.

Tamirou F, Husson SN, Gruson D et al (2017) Brief report: the Euro-lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-Mullerian hormone. Arthritis Rheumatol 69:1267–1271. https://doi.org/10.1002/art.40079CrossRefPubMed

27.

Brunner HI, Silva CA, Reiff A et al (2015) Randomized double-blinded dose escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 67:1377–1385. https://doi.org/10.1002/art.39024CrossRefPubMedPubMedCentral

28.

Haubitz M, Bohnenstengel F, Brunkhorst R et al (2002) Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 61:1495–1501. https://doi.org/10.1046/j.1523-1755.2002.00279.xCrossRefPubMed

29.

Chan EY, Lai FF, Ma AL et al (2024) Managing lupus nephritis in children and adolescents. Paediatr Drugs 26:145–161. https://doi.org/10.1007/s40272-023-00609-3CrossRefPubMed

30.

Eden G, Kuhn-Velten WN, Hafer C et al (2018) Enhanced elimination of cyclophosphamide by high cut-off haemodialysis: single-dose pharmacokinetics in a patient with cast nephropathy. BMJ Case Rep 2018:bcr2017221735. https://doi.org/10.1136/bcr-2017-221735CrossRefPubMedPubMedCentral

31.

Katsifis GE, Tzioufas AG, Vlachoyiannopoulos PG et al (2002) Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. Rheumatology 41:780–786. https://doi.org/10.1093/rheumatology/41.7.780CrossRefPubMed

32.

Houssiau FA, D’Cruz DP, Haga HJ et al (1991) Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study. Lupus 1:31–35CrossRefPubMed

33.

Houssiau FA, Vasconcelos C, D’Cruz D et al (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69:61–64. https://doi.org/10.1136/ard.2008.102533CrossRefPubMed

34.

Access Trial Group (2014) Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol 66:3096–3104. https://doi.org/10.1002/art.38790CrossRefPubMedCentral

35.

Wofsy D, Diamond B, Houssiau FA (2015) Crossing the Atlantic—the Euro-Lupus nephritis regimen in North America. Arthritis Rheumatol 67:1144–1146. https://doi.org/10.1002/art.39067CrossRefPubMedPubMedCentral

36.

Rovin BH, Adler SG, Barratt J et al (2021) Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100:753–779. https://doi.org/10.1016/j.kint.2021.05.015CrossRefPubMed

37.

Fanouriakis A, Kostopoulou M, Andersen J et al (2023) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15–29. https://doi.org/10.1136/ard-2023-224762CrossRef

38.

Fujinaga S, Kaneko K, Ohtomo Y et al (2005) Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children. Pediatr Nephrol 20:1500–1503. https://doi.org/10.1007/s00467-005-1983-9CrossRefPubMed

39.

Baskin E, Ozen S, Cakar N et al (2010) The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis. Pediatr Nephrol 25:111–117. https://doi.org/10.1007/s00467-009-1291-xCrossRefPubMed

40.

Wang CS, Sadun RE, Zhou W et al (2023) Renal response outcomes of the EuroLupus and NIH cyclophosphamide dosing regimens in childhood-onset proliferative lupus nephritis. Arthritis Rheumatol 76:469–478. https://doi.org/10.1002/art.42725CrossRef

41.

Cannon L, Wenderfer SE, Lewandowski LB et al (2022) Use of EuroLupus cyclophosphamide dosing for the treatment of lupus nephritis in childhood-onset systemic lupus erythematosus in North America. J Rheumatol 49:607–614. https://doi.org/10.3899/jrheum.210428CrossRefPubMedPubMedCentral

42.

Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156–1162CrossRefPubMed

43.

Isenberg D, Appel GB, Contreras G et al (2010) Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 49:128–140. https://doi.org/10.1093/rheumatology/kep346CrossRefPubMed

44.

Walsh M, Solomons N, Lisk L et al (2013) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the aspreva lupus management study. Am J Kidney Dis 61:710–715. https://doi.org/10.1053/j.ajkd.2012.11.042CrossRefPubMed

45.

Tang Z, Yang G, Yu C et al (2008) Effects of mycophenolate mofetil for patients with crescentic lupus nephritis. Nephrology 13:702–707. https://doi.org/10.1111/j.1440-1797.2008.00975.xCrossRefPubMed

46.

Cooper JC, Rouster-Stevens K, Wright TB et al (2018) Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis. Pediatr Rheumatol Online J 16:65. https://doi.org/10.1186/s12969-018-0279-0CrossRefPubMedPubMedCentral

47.

Smith E, Al-Abadi E, Armon K et al (2019) Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus 28:613–620. https://doi.org/10.1177/0961203319836712CrossRefPubMed

48.

Suhlrie A, Hennies I, Gellermann J et al (2020) Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study. Pediatr Nephrol 35:1235–1246. https://doi.org/10.1007/s00467-020-04501-xCrossRefPubMed

49.

Demir S, Gülhan B, Özen S et al (2021) Long term renal survival of pediatric patients with lupus nephritis. Nephrol Dial Transplant 37:1069–1077. https://doi.org/10.1093/ndt/gfab152CrossRef

50.

Chbihi M, Eveillard LA, Riller Q et al (2022) Induction therapy for pediatric onset class IV lupus nephritis: mycophenolate mofetil versus cyclophosphamide. J Nephrol 36:829–839. https://doi.org/10.1007/s40620-022-01438-2CrossRefPubMed

51.

Sundel R, Solomons N, Lisk L (2012) Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus 21:1433–1443. https://doi.org/10.1177/0961203312458466CrossRefPubMed

52.

Rovin BH, Teng YKO, Ginzler EM et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070–2080. https://doi.org/10.1016/s0140-6736(21)00578-xCrossRefPubMed

53.

Furie R, Rovin BH, Houssiau F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117–1128. https://doi.org/10.1056/NEJMoa2001180CrossRefPubMed

54.

Rovin BH, Furie R, Teng YKO et al (2022) A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 101:403–413. https://doi.org/10.1016/j.kint.2021.08.027CrossRefPubMed

55.

Brunner HI, Abud-Mendoza C, Viola DO et al (2020) Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis 79:1340–1348. https://doi.org/10.1136/annrheumdis-2020-217101CrossRefPubMed

56.

Gomez Mendez LM, Cascino MD, Garg J et al (2018) Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol 13:1502–1509. https://doi.org/10.2215/cjn.01070118CrossRefPubMedPubMedCentral

57.

Furie RA, Aroca G, Cascino MD et al (2021) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81:100–107. https://doi.org/10.1136/annrheumdis-2021-220920CrossRefPubMed

58.

Atisha-Fregoso Y, Malkiel S, Harris KM et al (2021) CALIBRATE: a phase 2 randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol 73:121–131. https://doi.org/10.1002/art.41466CrossRefPubMed

59.

Chan EY-H, Wong S-W, Lai FF-Y et al (2023) Long-term outcomes with rituximab as add-on therapy in severe childhood-onset lupus nephritis. Pediatr Nephrol 38:4001–4011. https://doi.org/10.1007/s00467-023-06025-6CrossRefPubMed

60.

Rovin BH (2009) Lupus nephritis treatment: are we beyond cyclophosphamide? Nat Rev Nephrol 5:492–494. https://doi.org/10.1038/nrneph.2009.130CrossRefPubMed

61.

Hogan J, Schwenk M, Radhakrishnan J (2012) Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? Kidney Int 82:1256–1260. https://doi.org/10.1038/ki.2012.203CrossRefPubMed

62.

Mok CC (2016) Con: Cyclophosphamide for the treatment of lupus nephritis. Nephrol Dial Transplant 31:1053–1057. https://doi.org/10.1093/ndt/gfw068CrossRefPubMed

63.

Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71:1400–1412. https://doi.org/10.1002/art.40930CrossRefPubMedPubMedCentral

64.

Bajema IM, Wilhelmus S, Alpers CE et al (2018) Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93:789–796. https://doi.org/10.1016/j.kint.2017.11.023CrossRefPubMed

Title: Do we really need cyclophosphamide for lupus nephritis?
Authors: Scott E. Wenderfer
Jennifer C. Cooper
Publication date: 12-04-2024
Publisher: Springer Berlin Heidelberg
Keywords: Lupus Nephritis
Mycophenolate Mofetil
Systemic Lupus Erythematosus
Published in: Pediatric Nephrology
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-024-06367-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Do we really need cyclophosphamide for lupus nephritis?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content